2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Transfusion, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1203 Targeting CCR2 restrains macrophage-associated hyperinflammation and autophagy-related dysfunction in hemophagocytic lymphohistiocytosis

Rong Huang, Heng Mei, MD, PhD2, Dawei Wang, PhD3, Tao Guo4
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome driven by uncontrolled immune activation, yet mechanism-based therapeutic options remain limited. Autophagy is an important regulator of inflammatory homeostasis, but its clinical and therapeutic relevance in HLH remains poorly defined.

Methods: Integrated bulk transcriptomic and single-cell RNA sequencing analyses were performed to identify autophagy-related candidate genes in HLH. Findings were validated using newly generated clinical RNA sequencing data, peripheral blood mononuclear cells from patients with HLH, LPS/IFN-γ stimulated macrophages, and CpG-induced secondary HLH-like mice. Plasma CCL2 was quantified by ELISA. CCR2 function was examined using the CCR2 inhibitor RS-504393 and siRNA-mediated CCR2 knockdown.

Results: We identified four autophagy-related candidate genes: CCR2, CDKN1A, TNFSF10, and TP53INP2, with CCR2 emerging as the leading target.Clinical RNA sequencing revealed broad inflammatory transcriptional remodeling in bone marrow and peripheral blood from patients with HLH. CCR2 was consistently upregulated in patient samples analyzed by RNA sequencing, patient peripheral blood mononuclear cells, inflammatory macrophages, and spleens from HLH-like mice.Higher CCR2 expression was associated with increased ferritin, IFN-γ, and IL-6 levels and lower platelet counts, while plasma CCL2 was also elevated in patients with HLH. In HLH-like mice, RS-504393 attenuated splenomegaly, hemophagocytosis, cytopenias, hyperferritinemia, hypertriglyceridemia, liver injury, inflammatory cytokine production, and plasma CCL2 levels. CCR2 blockade further reduced macrophage activation, ameliorated autophagy-related and mitochondrial abnormalities, and partially restored PI3K/AKT/mTOR phosphorylation. Concordant protective changes were observed after CCR2 knockdown in inflammatory macrophages.
Conclusions: CCR2 is a key regulator in HLH. It promotes macrophage hyperactivation and contributes to autophagy-related and mitochondrial dysfunction through the PI3K/AKT/mTOR pathway. These findings establish CCR2 as a biomarker of inflammatory activity and a therapeutically actionable target in HLH.

Rong Huang: No relevant conflicts of interest to declare.